Clinical Research
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 14, 2005; 11(46): 7290-7295
Published online Dec 14, 2005. doi: 10.3748/wjg.v11.i46.7290
Table 2 Risk of esophageal and lung cancer in patients with histologically confirmed esophagitis and without Barrett’s esophagus
Number ofcasesIncidence per 100 person-years of follow-up (95%CI)Expected numberof casesStandardized incidenceratio (95%CI)
OACAll patients0-1.350 ( -, 2.73)1
All esophageal cancersAll patients90.07 (0.04, 0.14)3.292.73 (1.25-5.19)
Men40.06 (0.02, 0.16)1.82.22 (0.61-5.69)
Women50.07 (0.02, 0.17)1.433.49 (1.14-8.16)
EsophagealAll patients30.02 (0.01, 0.07)1.022.93 (0.61-8.59)
SCC
Men10.02 (0, 0.10)0.442.28 (0.06-12.6)
Women20.03 (0, 0.12)0.593.40 (0.41-12.2)
Lung cancerAll patients210.16 (0.10, 0.24)19.711.07 (0.66-1.63)
Men160.25 (0.14, 0.40)11.361.41 (0.81-2.29)
Women50.07 (0.02, 0.17)7.630.66 (0.21-1.53)
Sensitivity analyses
Reclassified OAC2All patients60.04 (0.01, 0.13)2.272.64 (0.97-5.75)
Men30.05 (0.02, 0.11)1.362.20 (0.45-6.45)
Women30.04 (0.01, 0.13)0.853.54 (0.73-10.31)
Reclassified esophageal SCC3All patients90.07 (0.02, 0.17)1.944.64 (2.12-8.81)
Men40.06 (0.02, 0.16)0.914.39 (1.20-11.25)
Women50.07 (0.02, 0.17)1.024.92 (1.59-11.44)